Research Analysts’ Weekly Ratings Updates for BioNTech (BNTX)

Several analysts have recently updated their ratings and price targets for BioNTech (NASDAQ: BNTX):

• 12/11/2025 – BioNTech had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $140.00 price target on the stock.
• 12/11/2025 – BioNTech had its price target raised by analysts at Berenberg Bank from $150.00 to $155.00. They now have a “buy” rating on the stock.
• 12/4/2025 – BioNTech was upgraded by analysts at UBS Group AG to a “hold” rating.
• 12/3/2025 – BioNTech had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $151.00 price target on the stock.
• 11/25/2025 – BioNTech had its “buy” rating reaffirmed by analysts at Berenberg Bank.
• 11/17/2025 – BioNTech had its “buy” rating reaffirmed by analysts at Berenberg Bank.
• 11/12/2025 – BioNTech had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc..
• 11/10/2025 – BioNTech had its price target raised by analysts at HC Wainwright from $136.00 to $140.00. They now have a “buy” rating on the stock.
• 11/6/2025 – BioNTech had its price target raised by analysts at UBS Group AG from $115.00 to $117.00. They now have a “neutral” rating on the stock.
• 11/3/2025 – BioNTech had its “hold” rating reaffirmed by analysts at Cowen Inc.
• 11/3/2025 – BioNTech had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $134.00 price target on the stock.
• 11/3/2025 – BioNTech had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc..
• 10/23/2025 – BioNTech had its price target lowered by analysts at JPMorgan Chase & Co. from $121.00 to $120.00. They now have a “neutral” rating on the stock.
• 10/22/2025 – BioNTech had its price target lowered by analysts at Bank of America Corporation from $134.00 to $130.00. They now have a “buy” rating on the stock.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.